2022 Partners
Istari Oncology
Expertise Partner
Istari Oncology, Inc., headquartered in Research Triangle Park, North Carolina, is a privately held clinical-stage biotechnology company developing novel immunotherapies for the treatment of glioblastoma and a wide variety of solid tumors. Istari has licensed a broad range of patents and patent applications and has access to additional intellectual property to continue clinical and commercial development of these technologies. The company’s primary asset currently in clinical development is PVSRIPO. For more information, please visit: www.istarioncology.com
Kintara Therapeutics
Expertise Partner
Kintara Therapeutics is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara Therapeutics has teamed up with outstanding academic and clinical research institutions from around the world to support the development of our novel cancer therapies.
Medicenna Therapeutics
Expertise Partner
Medicenna is a clinical stage immunotherapy company engineering proprietary IL-2, IL-4 and IL-13 interleukins variants referred as Superkines, that can selectively modulate, fine-tune, or amplify specific immune response to tackle cancer, and autoimmune/inflammatory diseases. Medicenna's IL-4 Superkine, MDNA55, has been studied in 5 clinical trials including a Phase2b trial for recurrent GBM. MDNA55 has obtained Fast Track and Orphan Drug status from the FDA and FDA/EMA, respectively.
www.medicenna.com/pipeline/mdna55
Novocure
Expertise Partner
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development of its innovative therapy, Tumor Treating Fields. Novocure has ongoing clinical trials investigating Tumor Treating Fields in studies targeting specific lung, pancreatic, ovarian, hepatic, and gastric cancers, brain metastasis, and glioblastoma.
Samus Therapeutics
Hosting Partner
Samus Therapeutics, Inc. is a privately held, Boston-based biotechnology company focused on addressing areas of high unmet medical need in cancer and neurodegenerative diseases through a novel approach to protein degradation and restoration of normal cellular pathways. Samus has a broad proprietary technology platform with two clinical-stage lead small molecules targeting recurrent malignant glioma, myeloproliferative neoplasm, and neurodegenerative disorders including ALS and Alzheimer’s Disease.
Interested in Becoming a Partner?
